… Therefore, an economic evaluation of the treatment was conducted with rivaroxaban … analysis
for the Greek setting where the total lifetime cost was found lower for rivaroxaban treatment …

… In a Greek single-centre registry of patients hospitalized with AF, 13% of those with both AF
… In another Greek multi-centre cross-sectional study in 603 patients hospitalized for either HF …

… CONCLUSIONS: Dabigatran etexilate may represent a cost-… conduct an economic
analysis comparing treatment with clopi… a recent myocardial infarction from the Greek third-party-payer …

… meta-analysis between new oral agents in atrial fibrillation. … from the dabigatran 150 mg
arm of RE-LY was included in this analysis, because this was the Food and Drug Administration-…

… rivaroxaban (once daily), dabigatran etexilate (twice daily), … for Belgium15, Portugal17, and
Greece.A hypothetical cohort of … model and receives chronic treatment with rivaroxaban (20 …

… the switching from warfarin in non-valvular atrial fibrillation can be justified, not only on clinical
… for NOACs are in non-valvular atrial fibrillation. The review covers the period from January …

… of embolic complications of atrial fibrillation per a nominal … 1,177,846.50 RUB for dabigatran
etexilate and 1,177,846.50 … and amlodipine in the Greek market for the treatment of essential …

… In a previous systematic review and meta-analysis, we … with atrial fibrillation (AF) and stroke
or transient ischemic attack (TIA). This meta-analysis included trials of apixaban, dabigatran, …

… Dabigatran has been tested in the Randomized Evaluation of Long-term anticoagulant therapy
with dabigatran etexilate … study that compared 2 doses of dabigatran in patients with AF: …

… and effective for ischemic stroke prevention in patients with nonvalvular atrial fibrillation (NVAF).
We conducted a network meta-analysis (NMA) using published data from secondary …